Morningstar

Silence Therapeutics PLC ADR SLN

Stock XNAS Rating as of Oct 23, 2026

News

Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN

Business Wire Oct 21, 2026, 7:35:00 PM
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?

PR Newswire Oct 20, 2026, 4:21:00 PM
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

PR Newswire Oct 20, 2026, 12:59:00 PM
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders

Business Wire Oct 19, 2026, 1:40:00 PM
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

Global News Select Oct 19, 2026, 12:44:00 PM
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany

Business Wire Oct 19, 2026, 12:00:00 PM
Silence Therapeutics to Participate in Three September Investor Conferences

Business Wire Sep 2, 2026, 12:00:00 PM
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

Business Wire Aug 14, 2026, 8:55:00 PM
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Business Wire Aug 12, 2026, 3:20:00 AM
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Business Wire Aug 10, 2026, 8:01:00 PM
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Business Wire Aug 10, 2026, 11:30:00 AM
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Business Wire Aug 10, 2026, 11:15:00 AM
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Business Wire Aug 9, 2026, 9:00:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.